<DOC>
	<DOCNO>NCT02171481</DOCNO>
	<brief_summary>To establish bioequivalence two polymorph dabigatran etexilate , polymorph I polymorph II</brief_summary>
	<brief_title>Bioequivalence Two Different Polymorphs Dabigatran Etexilate Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Age ≥60 ≤85 year 3 . BMI ≥18.5 BMI ≤32.0 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation 1 . Clinically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Clinically relevant surgery gastrointestinal tract 3 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 4 . Any relevant bleeding history 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 10 . Participation another trial investigational drug within four week prior administration trial 11 . Alcohol abuse ( 60 g/day men 40 g/day woman ) 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior administration trial ) 14 . Excessive physical activity ( within one week prior administration trial ) 15 . Any laboratory value outside reference range clinical relevance 16 . Inability comply dietary regimen study centre 17 . Planned surgery within four week follow endof study examination 18 . Intake medication , influence blood clotting , i.e. , acetylsalicylic acid , coumarin etc . within 10 day prior administration 19 . Male subject agree minimise risk female partner become pregnant first dose day completion post study medical examination . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>